Twist-BRD4 Complex: Potential Drug Target for Basal-like Breast Cancer

Author(s): Jian Shi, Jingying Cao, Binhua P. Zhou

Journal Name: Current Pharmaceutical Design

Volume 21 , Issue 10 , 2015

Become EABM
Become Reviewer
Call for Editor


As an important basic helix-loop-helix (bHLH) transcription factor, Twist associates with several physiological processes such as mesodermal development, and pathological processes such as Saethre-Chotzen syndrome. During cancer progression, Twist induces epithelial-mesenchymal transition (EMT), potentiating cancer cell invasion and metastasis. Although many studies have revealed its multiple biological roles, it remained unclear how Twist transcriptionally acti vates targeted genes. Recently we discovered tip60-mediated Twist di-acetylation in the ‘‘histone H4-mimic’’ GK-X-GK motif. The di-acetylated Twist recruits BRD4 and related transcriptional components to super-enhancer of its targeted genes during progression of basal-like breast cancer (BLBC). Here, we review this new advance of regulation and functional mechanism of Twist.

Keywords: Twist, BRD4, epithelial-mesenchymal transition, basal-like breast cancer.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Published on: 11 December, 2014
Page: [1256 - 1261]
Pages: 6
DOI: 10.2174/1381612821666141211153853
Price: $65

Article Metrics

PDF: 68